These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31242909)

  • 1. NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal.
    Trinité B; Zhang H; Levy DN
    Retrovirology; 2019 Jun; 16(1):17. PubMed ID: 31242909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited HIV-1 Reactivation in Resting CD4
    Kumar A; Abbas W; Bouchat S; Gatot JS; Pasquereau S; Kabeya K; Clumeck N; De Wit S; Van Lint C; Herbein G
    Sci Rep; 2016 Dec; 6():38313. PubMed ID: 27922055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.
    Jochmans D; Anders M; Keuleers I; Smeulders L; Kräusslich HG; Kraus G; Müller B
    Retrovirology; 2010 Oct; 7():89. PubMed ID: 20950436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors.
    King RW; Klabe RM; Reid CD; Erickson-Viitanen SK
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1640-6. PubMed ID: 12019069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counteracting Akt Activation by HIV Protease Inhibitors in Monocytes/Macrophages.
    Pasquereau S; Kumar A; Abbas W; Herbein G
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29652795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equilibrium Model of Drug-Modulated GagPol-Embedded HIV-1 Reverse Transcriptase Dimerization to Enhance Premature Protease Activation.
    Sadiq SK; Mirambeau G; Meyerhans A
    AIDS Res Hum Retroviruses; 2018 Sep; 34(9):804-807. PubMed ID: 30056738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Balzarini J
    Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
    Moyle G
    Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
    Huruy K; Maier M; Mulu A; Liebert UG
    J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4
    Zerbato JM; Tachedjian G; Sluis-Cremer N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.
    Bonczkowski P; De Scheerder MA; Malatinkova E; Borch A; Melkova Z; Koenig R; De Spiegelaere W; Vandekerckhove L
    Sci Rep; 2016 Dec; 6():38329. PubMed ID: 27910923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.